IN8bio will present on gamma-delta T cell therapies at the IO360° Conference 2025 in Boston, March 24-26.
Quiver AI Summary
IN8bio, Inc., a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies for cancer and autoimmune diseases, will participate in the Immuno-Oncology 360° Conference 2025 from March 24-26 in Boston. CEO William Ho will co-chair Day 2 of the event on March 25, where he will deliver opening remarks and lead a session on the current state of the immuno-oncology market. Additionally, he will present at 4:35 PM EDT on the potential of IN8bio's gamma-delta T cell engager program, INB-619. This program aims to advance treatments for autoimmunity and oncology. For additional event coordination and information, interested parties are encouraged to contact the company directly.
Potential Positives
- IN8bio's participation and leadership at the Immuno-Oncology 360° Conference highlights the company's active engagement with key industry discussions and showcases its commitment to innovation in immunotherapy.
- William Ho's role as Co-Chair and presenter at the conference positions him as a thought leader in the field, which could enhance the company's visibility and reputation among peers and investors.
- The announcement of the session on INB-619 and its focus on gamma-delta T cell engagers emphasizes IN8bio's strategic direction in targeting both oncology and autoimmune diseases, which may attract interest from potential collaborators and investors.
Potential Negatives
- Participation in a major conference may highlight the company's need for further validation and interest in its innovative therapies, suggesting potential skepticism in the market about their effectiveness or commercial viability.
- The failure to disclose any recent clinical trial results or updates on their lead programs could raise concerns about the progress and status of their treatments, particularly in a competitive biopharmaceutical landscape.
- As a clinical-stage company, the emphasis on events without concrete achievements or partnerships may signal a lack of tangible advancements, which could affect investor confidence and perception of the company's prospects.
FAQ
What will William Ho discuss at the IO360° Conference 2025?
William Ho will discuss tackling tough questions in immuno-oncology for autoimmunity and present on gamma-delta T cell engagers.
When is the IO360° Conference 2025 taking place?
The IO360° Conference 2025 will be held from March 24-26, 2025, in Boston, MA.
How can I meet with IN8bio during the conference?
Interested individuals can coordinate a meeting with IN8bio by emailing [email protected].
What is IN8bio focusing on in their research?
IN8bio focuses on developing gamma-delta T cell therapies for cancer and autoimmune diseases.
Where can I find more information about the conference?
More information about the IO360° Conference can be found at https://io360summit.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INAB Hedge Fund Activity
We have seen 14 institutional investors add shares of $INAB stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FRANKLIN RESOURCES INC added 5,696,202 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,465,063
- ALYESKA INVESTMENT GROUP, L.P. added 4,628,482 shares (+1064.5%) to their portfolio in Q4 2024, for an estimated $1,190,445
- AIGH CAPITAL MANAGEMENT LLC added 4,517,227 shares (+269.7%) to their portfolio in Q4 2024, for an estimated $1,161,830
- ENSIGN PEAK ADVISORS, INC removed 829,176 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $213,264
- 683 CAPITAL MANAGEMENT, LLC removed 600,304 shares (-44.5%) from their portfolio in Q4 2024, for an estimated $154,398
- SIGMA PLANNING CORP added 190,100 shares (+22.3%) to their portfolio in Q4 2024, for an estimated $48,893
- GEODE CAPITAL MANAGEMENT, LLC added 185,919 shares (+56.5%) to their portfolio in Q4 2024, for an estimated $47,818
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB) , a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the Immuno-Oncology 360° (IO360°) Conference 2025, held March 24-26, 2025, in Boston, MA.
William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcoming remarks and discuss, “ Tackling the Tough Questions in IO for Autoimmunity Disease. ” After, he will Chair the session, “ State of the IO Market, Investments and Deals Plenary .”
During the afternoon session, at 4:35 PM EDT, Mr. Ho will present on the topic of “ Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager ,” and provide a corporate overview of IN8bio’s recently announced INB-619, T cell engager program for oncology and autoimmune diseases.
As co-chair and panelist, Mr. Ho expects to discuss the rationale and promise of a gamma-delta T cell engager in addressing autoimmunity, a rapidly emerging frontier for immunotherapies.
Presentation and Panel Details
Co-Chairs' Welcome & Tackling the Tough Questions in IO for Autoimmunity Disease
-
Date/Time: March 25, 2025, at 8:15 AM EDT
Picking Our Horse in the Race for Autoimmunity: The Gamma-Delta T Cell Engager
-
Date/Time: March 25, 2025, at 4:35 PM EDT
For those interested in coordinating a time to meet with the IN8bio during IO360°, please email [email protected] .
For more information about the event, visit https://io360summit.com .
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma, and advancing novel gamma-delta T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit
www.IN8bio.com
.
Investors & Company Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
[email protected]
IN8bio, Inc.
Patrick McCall
646.933.5603
[email protected]
Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
[email protected]
